Recall of Human Rabies Immunoglobulin by Bio Products Laboratory Limited
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin due to a stability failure and reduced potency.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 7, 2026 and geographically references National. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, mhra, Medicine.
What Happened
Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin following a stability failure, which has resulted in a reduction in potency of the product.
Which Products Are Affected
The affected product is Human Rabies Immunoglobulin 500IU solution for Injection from one specific batch, identified as EL(26)A/18. No model numbers, UPCs, quantities beyond one batch, or date ranges are specified in the alert.
What You Should Do
Consumers should stop using the affected batch and contact Bio Products Laboratory Limited for further instructions, as per the recall notice.
Why This Matters
This recall is significant because the reduced potency could compromise the effectiveness of the immunoglobulin in providing protection against rabies, potentially posing a serious health risk.
Source
This information is from the MHRA alert at https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bio-products-laboratory-limited-rabies-human-normal-immunoglobulin-500iu-solution-for-injection-el-26-a-slash-18.
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,061 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.